International Journal of Medical and All Body Health Research  |  e-ISSN: 2582-8940  |  Double-Blind Peer Review  |  Open Access  |  CC BY-NC-SA 4.0

Current Issues
     2026:7/4

International Journal of Medical and All Body Health Research

e-ISSN: 2582-8940 | Open Access

An update on the screening, diagnosis & management of breast cancer: A review with considerations for future fertility

Dr. Kulvinder Kochar Kaur, Dr. Gautam Allahbadia, Dr. Mandeep Singh

Scientific Director, Dr. Kulvinder Kaur Centre for Human Reproduction, GTB Nagar, Jalandhar, Punjab, India; Scientific Director, Ex-Rotunda-A Centre for Human Reproduction, Bandra (W), Mumbai, India; Consultant Neurologist, Swami Satyanand Hospital, Baradri, Ladowali Road, Jalandhar, Punjab, India

Article Information

Volume / Issue2 / 4 (October-December 2021)
Pages40-53
AccessOpen Access

Publication Timeline

  • Received26 October 2021
  • Accepted18 November 2021

Full Text (PDF)

Open Access - Free to Download

Download Full Article (PDF) JATS XML

Abstract

The diagnosis along with management of Breast cancer(BC) are going through a prototype switch from the one size fitting all towards the period of individualized medicine. With the advances in diagnosis that is inclusive of sophisticated methods like molecular imaging in addition to genomic expression profile aid in enhancement of tumor characteristics to get unraveled. With these diagnostics, in combination with the newer surgical strategies in addition to radiation therapy cause a strategy that is inclusive of multiple disciplines cooperating with each other for reduction of recurrence to the utmost minimum. Here we conducted a review utilizing search engine pub-med, google scholar; web of science; embrace; Cochrane review library utilizing the MeSH terms like surgery; presence or absence of estrogen receptor(ER);progesterone receptor(PR); human epidermal growth factor receptor (HER2),; chemotherapy; triple negative breast cancer(TNBC); endocrine therapy; metastases; radio therapy; imaging modalities; causes of TNBC; drug resistance; prognosis; markers for TNBC; effective tamoxifen; negative neo adjuvant chemotherapy; gene markers; role of microRNAs, from 1980’s till august 2021.We found a total of 442800 articles out of which we selected 86 articles for this chapter on update on breast cancer management. No meta-analysis was done. Further we have tried to explore a lot of modes by which TNBC treatment success can get escalated inclusive of the newer utilization of H2S pathway in cancer as well as mode by which it might work. Further with the escalated 5 yr survival along with advances in ovarian tissue cryopreservation oocyte cryopreservation prior to chemotherapy as well as radiotherapy one can consider ovarian tissue transplantation in such cases. With BCS an attempt at cosmetic surgery aids in women leading a more normal life. Thus we have tried to comprehensively detail all these features.

Keywords

Breast cancerdiagnosis screeningmanagementimagingtargeted treatmentradiationpathologyindividualized therapy

References

  1. Shiyanbola O, Arao R FMiglioretti DL, Sprague BL, Hampton JM, Stout NK, Kerlikowske K, et al. Emerging trends in family history of breast Cancer and associated risk. Cancer Epidemiol. Biomarkers Prev. 2017; 26(12):1753-1760, 10.1158/1055-9965.EPI-17-0531.International Journal of Medical and all body Health Research www.allmedicaljournal.com 51 [Google Scholar][Crossref]
  2. Jørgensen KJ, Gøtzsche PC, Kalager M, Zahl PH Breast Cancer Screening in Denmark: A Cohort Study of Tumor Size and Over diagnosis Ann. Intern. Med. 2017; 166(5):313-323, 10.7326/M16-0270. [Google Scholar][Crossref]
  3. Torre LA, Bray F, Siegel RL. Global cancer statistics, 2012 CA Cancer J. Clin. 2015; 65(2):87-108. [Google Scholar][Crossref]
  4. Desantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: convergence of incidence rates between black and white women CA Cancer J Clin. 2016; 66(1):31-42 [Google Scholar][Crossref]
  5. Fan L, Strasser-Weippl K., Li JJ, St Louis JDM, Finkelstein DM, Yu KD, et al. Breast cancer in China. Lancet Oncol. 2014; 15(7):e279-e289 [Google Scholar][Crossref]
  6. McDonald ES, Clark AS, Tchou JT, Zhang P, Freedman GM. Clinical diagnosis and management of Breast cancer. J Nucl Med. 2016; 57(2 Suppl 1):9S-16S. [Google Scholar][Crossref]
  7. Fuller MS, Lee CI, Elmer JG. Breast cancer screening: an evidence based. Med Clin North Am. 2015; 99:451-68. [Google Scholar][Crossref]
  8. Berry DA, Cronin KA, Plevritis SK, et al. Effect of Screening and adjuvant chemotherapy on mortality from breastcancer. N Engl J Med. 2005; 353:1784-92. [Google Scholar][Crossref]
  9. Pace LE, Keating NL. A systematic assessment of benefits and risks to guide Breast cancer Screening decisions. JAMA. 2014; 311:1327-35. [Google Scholar][Crossref]
  10. US Preventive service Task force. Breast cancer: Screening. http://www.us preventive service task force.org/Page/Topic/recommendation –summary/ breast-cancer- screening. Publized November 2009. Accessed November 2015. [Google Scholar][Crossref]
  11. Omega T, Beaber EF, Sprague BL, et al. Breast cancer Screening in an era of personalized regimens: A conceptual model and National cancer institute initiative for risk-based and preference based approaches at a population. Cancer 2014;120:2955-64. [Google Scholar][Crossref]
  12. Fried wald SM, Rafferty EA, Rose SL, et al. Breast cancer Screening using tomosynthesis in combination with digital mammography. JAMA. 2014; 311:2499-507. [Google Scholar][Crossref]
  13. Svahn TM, Houssami N, Schoupoulos I, Mattson R. Review of radiation dose estimate in digital breast tomosynthesis in two view full field digital mammography. Breast. 2015; 24:92-99. [Google Scholar][Crossref]
  14. Zuckeermann SP, Conant EP, Weinstein S, Synnestevdt M, Korhonen K, McDonald ES. Impact on recall rates following implementation of 2D mammography in digital breast- tomosynthesis – screening. In: Radiologic Society of North America 2015 Meeting Proceedings: November29-December 4, 2015; Cicago, IL. [Google Scholar][Crossref]
  15. Hall FM. Screening mammography guidelines: an alternative proactive approach. Radiology. 2014; 273:646-51. [Google Scholar][Crossref]
  16. Lehman CD. Clinical indications: what is the evidence. Eur J Radiol. 2012; 81(Suppl 1):S82-S84. [Google Scholar][Crossref]
  17. Berg WA. Tailored supplemental Screening for Breast cancer: what now and what next ? AJR. 2009; 192:390-99. [Google Scholar][Crossref]
  18. Berg WA, Blume JD, Cormack JB, et al. Combined Screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast-cancer. JAMA. 2008; 299:2151-63. [Google Scholar][Crossref]
  19. Brem RF, Lenihan MJ, Lieberman J, Torrente J. Screening breast ultrasound: past, present and future. AJR. 2015; 204:234-40. [Google Scholar][Crossref]
  20. Maniero MB, Lourenco A, Mahoney MC, et al. ACR appropriateness Criteria Breast cancer Screening. J Am Coll Radiol. 2013; 10:11-4. [Google Scholar][Crossref]
  21. Benner NC, Farah CS. Next generation sequencing in clinical oncology: next step towards clinical validation. Cancers (Basel). 2014; 6:2296-2312. [Google Scholar][Crossref]
  22. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumor. Nature. 2000; 406:747-52. [Google Scholar][Crossref]
  23. Ross JS, Linette JP, Stec J, et al. Breast cancer biomarkers and Molecular medicine. Expert Rev Mol Diagn. 2003; 3:573-85. [Google Scholar][Crossref]
  24. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in Breast cancer by immune his to chemical analysis. Mod Pathol. 1998; 11:155-68. [Google Scholar][Crossref]
  25. Lehman CD, Gatsonis C, Kuhl CK, et al. MRI evaluation of the contralateral breastin women with recently diagnosed Breast cancer. NEngl J Med. 2007; 356:1295-1303. [Google Scholar][Crossref]
  26. Houssami N, Turner R, Morrow M. Preoperative magnetic resonance imaging in Breast cancer: meta-analysis of surgical outcomes. Ann Surg. 2013; 257:249-55. [Google Scholar][Crossref]
  27. Houssami N, Turner R, Mackasil P, et al. An individual person data meta-analysis of preoperative magnetic resonance imaging and Breast cancer recurrence. J Clin Oncol. 2014; 32:392-401. [Google Scholar][Crossref]
  28. Berg WA, Gutierrez L, Ness Aiver MS, et al. Diagnostic accuracy of mammography, Clinical examination, US and MR imaging in preoperative assessment of Breast cancer. Radiology. 2004; 233:830-49. [Google Scholar][Crossref]
  29. Dorn PL, Al Hallaq HA, Haq F, et al. A prospective study of the utility of magnetic resonance imaging in determining candidacy for partial breast irradiation. Int J Radiol Oncol Biol Phys. 2013; 85:615-22. [Google Scholar][Crossref]
  30. Xu G, Zhao L, He Z. Performance of whole body PET/CT for the detection of distant malignancies in various cancers: a systematic review and, meta-analysis. J Nuc Med. 2012; 53:1847-54. [Google Scholar][Crossref]
  31. Fischer JP, Wes AM, Tuggle CT, et al. Mastectomy, with or without immediate implant reconstruction has similar 30 days perioperative outcomes. J Plast Reconstr Aesthet Surg. 2014; 67:1515-22. [Google Scholar][Crossref]
  32. Veronesi U, Saccozzi R, Del Vecchio M, et al. Comparing radical Mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers in the Breast. NEngl J Med. 1981; 305:6-11. [Google Scholar][Crossref]
  33. Gray RJ, Pockaj BA, Karstaedt PJ, Roarke MC. Radioactive seed localization of nonpalpable Breast lesions is better than Wire localization. Am J Surg. 2004; 188:370-80. [Google Scholar][Crossref]
  34. Silverstein MJ, Mai T, Savalia N, Vance F, Guerra L. Oncoplastic Breast conserving surgery:the new paradigm. J Surg Oncol. 2014; 110:82-89. [Google Scholar][Crossref]
  35. Condeiro PG. Breast reconstruction after surgery for Breast cancer. NEngl J Med. 2008; 359:1590-1601. [Google Scholar][Crossref]
  36. De La Cruz L, Moody AM, Tappy EE, Blankenship SA, Hecht EM. Overall survival, disease free survival and nipple areolar recurrence in the setting of Nipple sparing mastectomy: a meta-analysis and systematic review.Ann Surg Oncol. 2015; 22:3241-49. [Google Scholar][Crossref]
  37. Zhang H, Li Y, Moran MS, Haffty BG, Yang Q. Predictive factors of nipple involvement in Breast International Journal of Medical and all body Health Research www.allmedicaljournal.com 52 cancer: A systematic review and, meta-analysis. Breast Cancer Res Treat. 2015; 151:249-59. [Google Scholar][Crossref]
  38. Guiliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for Breast cancer. Ann Surg. 1994; 220:391-98. [Google Scholar][Crossref]
  39. Lucci A, McCall LM, Beitsch PD, et al. Surg ical complications associated with sentinel lymph node dissection (SLND)plus axillary lymph node dissection compared with SLND dissection alone in the American College of Surgeon’s Oncology GroupZ0011 trial. J Clin Oncol. 2007; 25:3657-63. [Google Scholar][Crossref]
  40. Guiliano AE, Hunt KK, Ballmann KV, et al. Axillary dissection vs no Axillary dissection in women withinvasive Breast Cancer with sentinel lymph node metastases:a escalated randomized clinical trial. JAMA. 2011; 305:569-75. [Google Scholar][Crossref]
  41. Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neo adjuvant chemotherapy in patients with node positive Breast Cancer: the ACOSOG Z1071(Alliance) clinical trial. JAMA. 2013; 310:1455-61. [Google Scholar][Crossref]
  42. Kuehn T, Bauerfiend I, Fehm T, et al. Sentinel lymph node biopsy in patients with Breast Cancer before and after neo adjuvant chemotherapy (SENTINA):A Prospective a multicentric cohort study. Lancet Oncol 2013; 14:609-18. [Google Scholar][Crossref]
  43. Paik S, Shak S, Tang G, et al. A multigene assay to predict occurrence of tamoxifen treated node negative Breast Cancer. NEngl J Med. 2004; 351:2817-26. [Google Scholar][Crossref]
  44. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay on post menopausal women with node positive, oestrogen receptor positive Breast Cancer on chemotherapy: a retrospective analysis of a randomized trial. Lancet Oncol. 2010; 11:55-65. [Google Scholar][Crossref]
  45. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor2 positive Breast Cancer: planned joint analysis of Overall survival from NSABP-31 and NCCTG N9831. J Clin Oncol. 2014; 32:3744-52. [Google Scholar][Crossref]
  46. Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node negative HER2 positive Breast Cancer. NEngl J Med. 2015; 372:134-41. [Google Scholar][Crossref]
  47. Mavroudis D, Saloustros E, Malamos N, et al. Six vs 12 monthsof Trastuzumab in combination with dose dense chemotherapy for women with HER2 positive Breast Cancer:a multicentre randomized study for the Hellenic Oncology Research Group(HORG). Am On col 2015; 26:1333-40. [Google Scholar][Crossref]
  48. Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in post menopausal Breast Cancer. NEngl J Med. 2014; 371:107-18. [Google Scholar][Crossref]
  49. Davies C, Pan H, Godwin J, et al. Long term effects of continuing adjuvant tamoxifen to 10years vs stopping at 5years after estrogen receptor positive Breast Cancer ATLAS: A randomized trial. Lancet. 2013; 381:805-16. [Google Scholar][Crossref]
  50. Schneweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with neo adjuvant-anthracycline –containing and anthracycline-free chemotherapy in patients with HER2 positive early Breast Cancer:a randomized phase IIcardiac safety study(TRYPHAENA). Ann Oncol. 2013; 24:2278-84. [Google Scholar][Crossref]
  51. Leal F, Liutti VT, Antuunes Dos Santos VC, et al. Neo adjuvant Endocrine therapy for resectable Breast Cancer: a systematic review and, meta-analysis. Breast. 2015; 24:406-12. [Google Scholar][Crossref]
  52. Finn RS, Crown JP, Lang I, et al. The cyclin – dependent kinase4/6 inhibitors palbocibib in combination with letrozole versus letrozole alone as first line treatment of estrogen receptor positive HER2 negative, advanced Breast Cancer(PALOMA-1/TRIO-18):a randomized phase 2 study. Lancet Oncol. 2015; 16:25-35. [Google Scholar][Crossref]
  53. Turner NC, Ro J, Andre F, et al. Palbocibib in hormone receptor- positive advanced Breast Cancer. NEngl J Med. 2015; 373:209-19. [Google Scholar][Crossref]
  54. Swain SM, Baselga J, Kim SB, et al. pertuzumab, trastuzumab and docetaxel in HER2 positive metastatic Breast Cancer. NEngl J Med. 2015; 372:724-34. [Google Scholar][Crossref]
  55. Krop IE, Kim SB, Gonzalez-Martin A, et al. Trastuzumab emtansine versus treatment of a physician’s choice for pretreated HER2 positive advanced Breast Cancer(TH3RESA):a randomized open label, phase 3 trial. Lancet Oncol. 2014; 15:689-99. [Google Scholar][Crossref]
  56. Jatoi I, Proschan MA. Randomized trials of breast conserving therapy versus Mastectomy for primary Breast Cancer:a pooled analysis of updated results. AmJ Clin Oncol. 2005; 28:289-94. [Google Scholar][Crossref]
  57. Haviland JS, A’Hern R, Bentzen SM, Whelan T, Bliss JM. Radiotherapy for Breast Cancer, the TARGIT-A trial. Lancet. 2014; 383:1716-17. [Google Scholar][Crossref]
  58. Whaley JT, Lester Col NH, Morrissey SM, Milby AM, Hwang WT, Prosnitz RZ. Use of post excision preirradiation mammography in patients with ductal carcinoma in situ treated with breast conserving therapy. Pract Radiot Oncol. 2013; 3:e107-e112. [Google Scholar][Crossref]
  59. Keller LM, Sopka DM, Li T, et al. Five year results of whole breast intensity Fox modulated radiation therapy for the treatment of early stage Breast cancer: the Fox Chase Cancer center experience. Int J Radiol Oncol Biol Phys. 2012; 84:881-87. [Google Scholar][Crossref]
  60. Eldredge –Hindy H, Lockamy V, Crawford A, et al. Active breathing coordination reduces radiation dose to the heart and preserves local control in patients with left Breast Cancer: report of a prospective trial. Pract Radiot Oncol. 2015; 5:4-10. [Google Scholar][Crossref]
  61. McCormick B, Winter K, Hudis C, et al. RTOG 9804:A prospective randomized trial for good –risk ductal carcinoma in situ of the breast comparing radiotherapy with observation. J Clin On col. 2015; 33:709-15. [Google Scholar][Crossref]
  62. Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early Breast cancer: long term follow up of CALGB9343. J Clin Oncol. 2013; 31:2382-87. [Google Scholar][Crossref]
  63. Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: A trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009; 27:5319-24. [Google Scholar][Crossref]
  64. RobertsonI J, Hand F, Kell MR. FDG-PET/CT in Breast cancer in the staging of local/regional metastasis in Breast Cancer. Breast. 2011; 20:491-94. [Google Scholar][Crossref]
  65. Wheelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal radiation in early stage Breast cancer. NEngl J Med. 2015; 372:307-16. [Google Scholar][Crossref]
  66. Ng SP, David S, Alamgeer M, Ganju V. Impact of pretreatment combined 18F Fluoro‒D–Glucose positron emission tomography / computed tomography staging on radiation therapydecisions in locally advanced Breast International Journal of Medical and all body Health Research www.allmedicaljournal.com 53 cancer. Int J Radiol Oncol Biol Phys. 2015; 93:111-17. [Google Scholar][Crossref]
  67. Gradishar WJ, Anderson BO, Blair SL, et al. Breast Cancer version 3.2014. J Natl Compr Conc Netw. 2014; 12:542-90. [Google Scholar][Crossref]
  68. McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgeryon 10 year recurrence and 20 year Breast Cancermortality: meta-analysis of individual patient data for 8135 women in 22 randomized trials. Lancet. 2014; 383:2127-35. [Google Scholar][Crossref]
  69. Haviland JS, Owen JR, Dewar JA, et al. Standardisation of Breast radiotherapy (START)trials of radiotherapy Hypofractionationation for treatment of early stage Breast cancer: 10 year follow up of two randomized controlled trials. Lancet Oncol. 2013; 14:1086-94. [Google Scholar][Crossref]
  70. Bekelman JE, Sylwestrzak G, Barron J, et al. Uptake and costs of Hypofractionation vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008-2013. JAMA. 2014; 312:2542-50. [Google Scholar][Crossref]
  71. Beitsch PD, Shaitelman SF, Vicini FA. Accelerated partial breast irradiation. J Surg Oncol. 2011; 103:362-68. [Google Scholar][Crossref]
  72. Warrier S, Tapia G, Golsman D, Beith J. An update in Breast Cance screening and Management Women’s Health. 2016; 12(2):229-39. [Google Scholar][Crossref]
  73. Kulvinder Kochar Kaur, Allahbadia GN, Singh M. Novel ways of targeting triple negative breast cancer(TNBC) with the latest research-Will it improve prognoses. J Gynaecol, 2019. [Google Scholar][Crossref]
  74. Wu S, Zhou J, Zhang K, Chen H, Luo M, Lu Y, et al. Molecular Mechanisms of PALB2Function and Its Role in Breast Cancer Management. Front. Oncol. 2019; 10:301. [Google Scholar][Crossref]
  75. Wang RH, Chu YH, Lin KT. The Hidden Role of Hydrogen Sulfide Metabolism in Cancer. Int. J. Mol. Sci. 2021; 22:6562. https://doi.org/10.3390/ijms22126562 [Google Scholar][Crossref]
  76. Lia H, Zub X, Gaoa G, Gaoa X, Wu Bo, Zhengd G, et al. Hydrogen sulfide and its donors: Novel antitumor and antimetastatic therapies for triple-negative breast cancer. Redox Biology. 2020; 34:101564. [Google Scholar][Crossref]
  77. Huang S, Fan P, Zhang C, Xie J, Gu X. Exosomal microRNA-503-3p derived frommacrophages represses glycolysis and promotes mitochondrial oxidative phosphorylation in breastcancer cells by elevating DACT2. Cell Death Discovery. 2021; 7:119. https://doi.org/10.1038/s41420-021-00492-2 [Google Scholar][Crossref]
  78. Zangouei AS, Alimardani M, Moghbeli M. MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells. Cancer Cell Int. 2021; 21:213. doi: 10.1186/s12935-021-01873-4. [Google Scholar][Crossref]
  79. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7):2750-2767. [Google Scholar][Crossref]
  80. Kulvinder Kochar Kaur, Allahbadia GN, Singh M. Role of Nutrients Competition in Immunometabolism -Effects on Immune Responses - A Systematic Review". Acta Scientific Nutritional Health. 2019: 3(10):197-204. [Google Scholar][Crossref]
  81. Shi J, Li F, Song Y. Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer. Cancer Manag Res. 2020; 12:9375-9387. [Google Scholar][Crossref]
  82. Xing X, Fan Z, Gao Y, Li Z. High Prevalence of Triple-Negative Breast Cancer in Southern Shaanxi Province, China. Cancer Manag Res. 2021; 13:1609-1615. [Google Scholar][Crossref]
  83. Kulvinder Kochar Kaur, Allahbadia GN, Singh M. Advances in the Treatment of Breast Cancer-Emphasis on fertility –preservation A Case Report. J Gynaecol Res. 2017; 3(1):1-6. [Google Scholar][Crossref]
  84. Perri T, Lifshitz D, Sadesdzki S, Oberman B, Meirow D, Ban-Baruch G, et al. Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers. Fertil Steril. 2021; 116(2):338-47. [Google Scholar][Crossref]
  85. García-Planells J, Simon Frances B, Diez-Juan A. BRCA, breast cancer and in vitro fertilization: How should we advise our patients? Fertil Steril. 2021; 116(2):359-60. [Google Scholar][Crossref]

How to Cite

Kaur, K. K., Allahbadia, G., & Singh, M. (2021). An update on the screening, diagnosis & management of breast cancer: A review with considerations for future fertility. International Journal of Medical and All Body Health Research, 2(4), 40-53.

Kaur, Kulvinder Kochar, et al. "An update on the screening, diagnosis & management of breast cancer: A review with considerations for future fertility." International Journal of Medical and All Body Health Research, vol. 2, no. 4, 2021, pp. 40-53.

Kaur, K. K., Allahbadia, G. and Singh, M. (2021) 'An update on the screening, diagnosis & management of breast cancer: A review with considerations for future fertility', International Journal of Medical and All Body Health Research, 2(4), pp. 40-53.

Kaur KK, Allahbadia G, Singh M. An update on the screening, diagnosis & management of breast cancer: A review with considerations for future fertility. International Journal of Medical and All Body Health Research. 2021;2(4):40-53.

Similar Articles

Share

Find this Article on

Google Scholar Semantic Scholar OpenAlex ResearchGate BASE

A newly published article may take a few days to appear on these services.